Trials / Active Not Recruiting
Active Not RecruitingNCT03140358
The Use of Atropine 0.01% in the Prevention and Control of Myopia (ATOM3)
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 300 (actual)
- Sponsor
- Singapore National Eye Centre · Other Government
- Sex
- All
- Age
- 5 Years – 9 Years
- Healthy volunteers
- Accepted
Summary
Study of low dose atropine in preventing the onset and progression of myopia in high risk children with pre-myopia or low-myopia.
Detailed description
High risk children (with family history of myopia) with low hyperopia or low myopia will be randomized to atropine or placebo, with 2 -2.5 year treatment and 1 year washout.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atropine sulfate 0.01% | Atropine 0.01% |
| DRUG | Placebo | placebo |
Timeline
- Start date
- 2017-04-21
- Primary completion
- 2024-12-31
- Completion
- 2025-12-31
- First posted
- 2017-05-04
- Last updated
- 2025-05-18
Locations
1 site across 1 country: Singapore
Source: ClinicalTrials.gov record NCT03140358. Inclusion in this directory is not an endorsement.